Marietjie has been practising as an attorney since 2001 and holds the degrees of BProc, LLB, LLM with specialisation in Intellectual Property Law and an LLD with specialisation in Biotechnology Law. During her years as partner at Dyason Inc in Pretoria she drafted, reviewed and advised on Health-tech, Fin-tech and Bio-tech Contracts, advised on all legal aspects involving Biotechnology, litigated and gave legal advice in the fields of Health Care, Life Sciences and Insurance. In 2019 Marietjie went solo to pursue her passion for law, science and art, and founded Biolawgic (Pty) Ltd, a private company providing legal, bioethics, consulting and training services tailor made for the specialised needs of role players in Health Care, Biotechnology, Life Sciences and the pharmaceutical industry. The past year Marietjie specifically focussed on and was involved in genetic research regulation, privacy issues relating to health information, data sharing and commercialisation, gene editing, stem cell therapy ethics and research regulations, the ethics and regulation of social media crowdsourcing, surrogacy applications and biobank start-ups and the visualisation of informed consent forms for rare disease biobanks scientific research.
Marietjie has published numerous articles in both national and international journals on these topics, including being the lead author on the chapter in a book about international stem cell research regulation and translational therapies that was published by Springer Nature. Her doctoral studies about informed consent in the context of genomic research involving the indigenous San populations of southern Africa has won her both national and international research awards and resulted in her pioneering a visual communication tool to bridge communication gaps between scientists and research participants. In 2019 she also joined the University of Kwa-Zulu Natal’s Health Law and Bioethics flagship as a post-doctoral research fellow, which keeps her digging through the latest legal and ethical developments in gene editing and related issues.